한국어
Quantus

Bon Natural Life

BON · Nasdaq
$1.16+2.86%
2026-09-04 close

Bon Natural Life last closed at $1.16 (+2.86%) on 2026-09-04. Listed on Nasdaq; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
277 picks
Next-day win rate
44.2%
Avg next-day
-0.28%
vs market
-0.51%p

Every new-high-plus-volume pick we actually published (US market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

C+
Overall: 건강관리 459/745 · top 62%
Factor composite · relative position in sector

PER 11.8 · PBR 0.11 — own-history percentile 23/100 · 90/100

Open self-history band
PER23/100
PBR90/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 6.40
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
6.40
Beneish M-Score
-0.32

Statistical manipulation-risk signal

Sloan accrual
13.15%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

매출 하락 → 마진 압박 → 현금 악화

Critical

매출이 -19.2% 감소하며 영업이익률이 20.0%에서 7.9%로 하락했다. 영업현금흐름도 동반 감소하여 수익-현금 순환이 약화되고 있다.

Evidence

매출 YoY -19.2% (2023→2024)영업이익률 20.0%→7.9%영업CF -1→-8

차입 증가 → 이자부담 → 수익성 악화

Critical

부채가 +61.3% 늘며 이자보상배율이 24.8x에서 6.2x로 하락했다. ROE도 16.7%에서 4.3%로 낮아져 차입 부담이 수익성을 누르고 있다.

Evidence

부채 YoY +61.3%이자보상배율 24.8x→6.2xROE 16.7%→4.3%

운전자본 팽창 → 현금 고갈 → 유동성 위기

Warning

순운전자본이 +137.5% 팽창하며 현금이 묶이고 있다. 영업CF/순이익 비율이 -1940%로 이익 대비 현금 회수가 부족하고, 유동비율도 2.52에서 2.42로 하락했다.

Evidence

순운전자본 YoY +137.5%영업CF/순이익 -1940%유동비율 2.52→2.42

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

1/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score1/9

Profitability

  • Positive ROAPass
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Not passed

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -32%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Revenue qualityWarning

OCF/매출 3기 연속 하락. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (20.0% → 7.9%, -12.2%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

USAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 379 of 543, share 0%.

379 / 5430%revenue share

Who dominates this industry?

  1. 1CVS Health14.1%
  2. 2McKesson13.6%
  3. 3Cigna9.4%
  4. 4Cardinal Health8.4%
  5. 5Centene6.2%
  6. 6Bon Natural Life0%

Concentration

DistributedCR3 37.1%
HHI 642543 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
159.97
Direction
축소
Level
넓음
Years
21

Value lens

P90/P10
24.4
Median P/B
3.02
Level
넓음
n
463

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
7.9%
Interest coverage
6.2x
Return on equity (ROE)
0.9%

Operating margin −5pp

Severe margin pressure
Interest coverageBase 6.2x adverse case 2.2x
Return on equity (ROE)Base 0.9% adverse case 0.9%

Revenue −15%

Tolerable
Interest coverageBase 6.2x adverse case 5.3x
Return on equity (ROE)Base 0.9% adverse case 2.9%

Interest rate +2pp

Tolerable
Interest coverageBase 6.2x adverse case 2.8x
Return on equity (ROE)Base 0.9% adverse case 2.8%

Interest coverage limit

Current margin 6.6pp

Interest coverage limit at an operating margin of 1.3%

Interest expense coverage threshold

Connections

AI-extracted related companies · for reference

Competitors
HerbalifePrice comovement r=0.01 (1 year)AmwayNature's BountyNOW Foods
🔗 See in the full market map →

Recent filings

Filings for overseas stocks are on the way. For now we cover Korean stocks only.

About Bon Natural Life
What technical signals does Bon Natural Life (BON) have?
Bon Natural Life current technical signals: no active technical signal.
Is Bon Natural Life a cup-and-handle pattern?
No. Bon Natural Life has no valid cup-and-handle signal right now.
What are Bon Natural Life's financials and valuation?
Bon Natural Life's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy